Prot #1289.6: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable ant

Project: Research project

Project Details

StatusFinished
Effective start/end date1/29/15 → 1/29/18

Funding

  • DrugDev Inc. (Prot #1289.6 // Prot #1289.6)
  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1289.6 // Prot #1289.6)